On the one hand, 2.4% of 2059 samples had a higher expression of ITGB2-AS1 in METABRIC breast cancer sub-database on cBioPortal online website [20,21,22], and higher expression group had a poorer overall survival rate (p < 0.05). This evidence concerns the gene ITGB2 and breast carcinoma.